Review



th17 b condition  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems th17 b condition
    FIGURE 4. <t>Th17</t> cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.
    Th17 B Condition, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 419 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/th17+b+condition/Recombinant+Mouse+TGF-beta+1+Protein/pm32518131-61-5-14
    Average 96 stars, based on 419 article reviews
    th17 b condition - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways."

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.

    Journal: ImmunoHorizons

    doi: 10.4049/immunohorizons.2000008

    FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.
    Figure Legend Snippet: FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.

    Techniques Used:

    FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data
    Figure Legend Snippet: FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data

    Techniques Used: Expressing, Control, Quantitative RT-PCR

    Related Articles

    Expressing:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Control:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Quantitative RT-PCR:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Derivative Assay:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    In Vitro:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Gene Expression:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Two Tailed Test:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Activation Assay:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    In Vivo:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Labeling:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Binding Assay:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Inhibition:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Western Blot:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).

    Irradiation:

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.
    Article Snippet: 16-0038-85, 5mg/ml; Thermo Fisher Scientific) and anti-CD28 mAb (catalog no. 16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).16- 0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral conditions (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific] and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]). ... The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.. 1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems] and catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]), Treg condition (catalog no. 402-ML-020, 5 ng/ml IL-2 [R&DSystems]; catalog no. 7666-MB-005, 2.5 ng/ml TGF-b1 [R&D Systems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), and Th0 condition (catalog no. 16- 7041-95, 10mg/ml anti–IL-4mAb [Thermo Fisher Scientific] and catalog no. 16-7311-38, 10mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]).1887-ML-010, 20ng/ml IL-23 [R&DSystems]; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb [Thermo Fisher Scientific]; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb [Thermo Fisher Scientific]), Th1 condition (catalog no. 419-ML010, 10 ng/ml IL-12 [R&D Systems]..

    Article Title: Inhibition of Glycolysis in Pathogenic T H 17 Cells through Targeting a miR -21-Peli1 -c-Rel Pathway Prevents Autoimmunity.
    Article Snippet: Naive CD4+ T cells were isolated from lymph nodes or spleen of 6–8-wk-old mice using a Naive CD4+ T Cell Isolation Kit (catalog no. 130-104-453; Miltenyi Biotec) according to the manufacturer’s instruction.. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 mAb (catalog no. 16-0038-85, 5 mg/ml; Thermo Fisher Scientific) in the presence of antiCD28 mAb (catalog no. 16-0289-85, 2 mg/ml; Thermo Fisher Scientific) in a 48-well plate under neutral condition (catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), TH17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1; R&D Systems; catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific), and TH17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6; R&D Systems; catalog no. 401-ML-025, 20 ng/ml IL-1b; R&D Systems; catalog no. 1887-ML-010, 20 ng/ml IL-23; R&D Systems; catalog no. 16-7041-95, 10 mg/ml anti–IL-4 mAb; Thermo Fisher Scientific; and catalog no. 16-7311-38, 10 mg/ml anti–IFN-g mAb; Thermo Fisher Scientific).. Cells were cultured in complete IMDM medium (Life Technology) supplemented with 10% FBS and 2-ME (1:1000).



    Similar Products

    th17 b condition  (R&D Systems)
    96
    R&D Systems th17 b condition
    FIGURE 4. <t>Th17</t> cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.
    Th17 B Condition, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/th17+b+condition/Recombinant+Mouse+TGF-beta+1+Protein/pm32518131-61-5-14
    Average 96 stars, based on 1 article reviews
    th17 b condition - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.

    Journal: ImmunoHorizons

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.

    doi: 10.4049/immunohorizons.2000008

    Figure Lengend Snippet: FIGURE 4. Th17 cell–intrinsic miR-22 deletion exacerbates autoimmune EAE.

    Article Snippet: The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.

    Techniques:

    FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data

    Journal: ImmunoHorizons

    Article Title: The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.

    doi: 10.4049/immunohorizons.2000008

    Figure Lengend Snippet: FIGURE 5. miR-22 represses Th17 cell pathogenicity by targeting PTEN-regulated pathway. (A) Expression profile of pathogenicity signature genes of the pathogenic Th17 cells from control and miR-222/2 are measured by qRT-PCR. Data

    Article Snippet: The following conditions were used: Th17 (b) condition (catalog no. 7666-MB-005, 2 ng/ml TGF-b1 [R&D Systems]; catalog no. 406-ML-025, 20 ng/ml IL-6 [R&DSystems]; catalog no. 16-7041- 95, 10mg/ml anti–IL-4mAb [ThermoFisher]; and catalog no. 16- 7311-38, 10 mg/ml anti–IFN-gmAb [Thermo Fisher Scientific]), Th17 (23) condition (catalog no. 406-ML-025, 20 ng/ml IL-6 [R&D Systems]; catalog no. 401-ML-025, 20 ng/ml IL-1b [R&D Systems]; catalogno.

    Techniques: Expressing, Control, Quantitative RT-PCR